Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Methoxsalen
Drug ID BADD_D01420
Description A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation.
Indications and Usage For the treatment of psoriasis and vitiligo
Marketing Status approved
ATC Code D05AD02; D05BA02
DrugBank ID DB00553
KEGG ID D00139
MeSH ID D008730
PubChem ID 4114
TTD Drug ID D08SKH
NDC Product Code 62991-2896; 64067-216; 64380-752; 72643-011; 62350-0049
UNII U4VJ29L7BQ
Synonyms Methoxsalen | Xanthotoxin | 8-Methoxypsoralen | 8 Methoxypsoralen | Ammoidin | Deltasoralen | Dermox | Geroxalen | Meladinina | Methoxa-Dome | Methoxa Dome | Oxsoralen | Méladinine | Meladinine | Oxsoralen-Ultra | Oxsoralen Ultra | Puvalen | Ultramop | 8-MOP | 8 MOP | 8MOP | Meloxine
Chemical Information
Molecular Formula C12H8O4
CAS Registry Number 298-81-7
SMILES COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Photosensitivity reaction23.03.09.0030.001406%
Presyncope02.11.04.013; 24.06.02.010; 17.02.05.0090.002031%
Pruritus23.03.12.001--
Psoriasis23.03.14.002; 10.02.01.036--Not Available
Pulmonary embolism24.01.06.001; 22.06.02.0010.004687%Not Available
Pyrexia08.05.02.0030.004271%
Rash23.03.13.001--Not Available
Rash vesicular23.03.13.009--Not Available
Skin discolouration23.03.03.0050.001146%Not Available
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.003--Not Available
Skin hyperpigmentation23.05.01.003--
Skin hypopigmentation23.05.02.003--
Squamous cell carcinoma16.16.01.0020.000521%Not Available
Sunburn23.03.09.007; 12.05.02.001--Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.0080.000521%
Systemic lupus erythematosus15.06.02.003; 10.04.03.004; 23.03.02.006--Not Available
Tenderness08.01.08.005--Not Available
Tension19.06.02.005--Not Available
Thrombosis24.01.01.0060.001042%Not Available
Urticaria10.01.06.001; 23.04.02.001--
Vertigo17.02.12.002; 04.04.01.003--
Visual impairment06.02.10.0130.000521%Not Available
Vomiting07.01.07.0030.001562%
Wheezing22.03.01.0090.001406%
Deep vein thrombosis24.01.02.0030.000521%Not Available
Haemorrhage24.07.01.0020.000781%Not Available
Adverse event08.06.01.0100.001146%Not Available
Inflammation10.02.01.089; 08.01.05.007--Not Available
Ill-defined disorder08.01.03.049--Not Available
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages